Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 16 July

Sophia Mavridis
July 16, 2021

Morning Bell 15 July

Paulina Peters
July 15, 2021

Morning Bell 14 July

Jessica Amir
July 14, 2021

Morning Bell 13 July

Jessica Amir
July 13, 2021

Morning Bell 12 July

Jessica Amir
July 12, 2021

Weekly Wrap 9 July

Jessica Amir
July 9, 2021

Morning Bell 9 July

Paulina Peters
July 9, 2021

Morning Bell 8 July

Jessica Amir
July 8, 2021

Morning Bell 7 July

Sophia Mavridis
July 7, 2021

Morning Bell 6 July

Jessica Amir
July 6, 2021

Morning Bell 5 July

Jessica Amir
July 5, 2021